FindTrial
Sign In

Reduction in interleukin-5 and other eosinophil biomarkers by full-house endoscopic sinus surgery in the treatment of severe nasal polyps

Reduction in interleukin-5 and other eosinophil biomarkers by full-house endoscopic sinus surgery in the treatment of severe nasal polyps

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20200530002
Enrollment
20
Registered
2020-05-30
Start date
2020-07-01
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic rhinosinusitis Nasal polyp Chronic rhinosinusitis Nasal polyp CRSwNP Eosinophil Eosinophilic Eosinophilia interleukin&#45

Interventions

Chronic rhinosinusitis with nasal polyps patients undergo full&#45
house endoscopic sinus surgery ,Patients in this arm serves as an untreated comparison group during the study&#44
but will eventually go on to receive full&#45
house endoscopic sinus surgery later at 4 weeks
Active Comparator Procedure/Surgery,No Intervention No treatment
Full&#45
house endoscopic sinus surgery ,No intervention group

Sponsors

Department of Otolaryngology, Faculty of medicine, Chulalongkorn University
Lead Sponsor
Endoscopic Nasal and Sinus Surgery Excellence Center King Chulalongkorn Memorial Hospital
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Any CRSwNP patient is defined as the presence of two or more symptoms for > 12 weeks, one of which should be: either nasal blockage/obstruction/congestion or nasal discharge (anterior/posterior nasal drip) ± facial pain/pressure ± reduction or loss of smell AND along with endoscopic and radiographic evidence of nasal polyps, grade ≥2 and diffuse bilateral mucosal inflammation AND have indication for sinus surgery **grade 0 being no visible polyps; grade 1 being polyps confined to the middle meatus; grade 2 being polyps beyond the middle meatus but not completely obstructing the nasal cavity; and grade 3 being polyps completely obstructing the nasal cavity

Exclusion criteria

Exclusion criteria: 1. prior sinus surgery 2. unilateral sinus changes 3. sinus disease associated with systemic conditions 4. under the age of 18 5. pregnant women 6. undertaking systemic and intranasal steroids and immunosuppressive medication during the past month

Design outcomes

Primary

MeasureTime frame
Effects on interleukin-5, soluble IL-5Rα nasal and serum level reduction by endoscopic sinus surger 4 weeks Measure these biomarker at baseline and 4 weeks time point—

Secondary

MeasureTime frame
Effects on eosinophil byproducts nasal and serum level reduction by endoscopic sinus surgery 4 weeks Measure nasal and serum level of ECP, eotaxin and serum eosinophil at baseline and 4 weeks timepoint—

Countries

Thailand

Contacts

Public ContactJuthaporn Phetpong

King Chulalongkorn Memorial hospital

juthapornp.md@gmail.com+66869262337

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026